Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Prediction: This Is What Eli Lilly Stock Will Do Next (Hint: It's Not a Stock Split)
With a market capitalization of over $800 billion, Eli Lilly (NYSE: LLY) is the largest pharmaceutical company in the world. Much that is thanks to the rise of glucagon-like peptide-1 (GLP-1) agonists such as Mounjaro and Zepbound, which are fueling a new wave of growth for the company.
Eli Lilly & Co. stock underperforms Thursday when compared to competitors
Shares of Eli Lilly & Co. LLY slid 1.65% to $909.32 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.40% to 5,745.37 and the Dow Jones Industrial Average DJIA rising 0.62% to 42,175.11.
Is Trending Stock Eli Lilly and Company (LLY) a Buy Now?
Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
3d
on MSN
Prediction: Eli Lilly Will Dominate the Billion-Dollar Weight Loss Drug Market for This Key Reason
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
15h
on MSN
The secrets to success that Microsoft, Meta, Lilly and Texas Instruments all share
Here, Hancock cites fund holding Eli Lilly and its patents on GLP-1 weight loss drugs Mounjaro and Zepbound. Hancock expects ...
16h
Eli Lilly & Co: Strong Buy Rating Amid Robust Product Growth and Promising Pipeline
Analyst Chris Schott from J.P. Morgan maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and keeping the price target ...
BioSpace
3d
Lilly Is Not ‘Feeling the Bern’ on Drug Prices Like Novo: Why the Double Standard?
Sen. Bernie Sanders’ aggressive targeting of Danish drugmaker Novo Nordisk’s Ozempic and Wegovy pricing, and not Eli Lilly’s ...
7h
Tradepulse Power Inflow Alert: Eli Lilly And Company Climbs 15 Points
ELI LILLY Inc. LLY today experienced a Power Inflow, a significant event for those who follow where smart money goes and ...
11d
Lilly Wants Records of People Who Took Weight-Loss Knockoffs
Eli Lilly & Co. is asking people who took copies of its blockbuster weight loss drug to give the company access to their ...
17h
Eli Lilly: Ebglyss To Challenge Dupixent In Atopic Dermatitis
Eli Lilly's Ebglyss gains FDA approval for atopic dermatitis treatment, poised to rival Dupixent with strong performance in ...
6d
on MSN
Eli Lilly's Alzheimer's drug approved in Japan
Eli Lilly said on Tuesday Japan's health ministry has approved donanemab, its drug for Alzheimer's disease, providing ...
Community Impact Newspaper
20h
Tiger Lilly event venue launching soon in former Estelle's space in downtown Austin
Tiger Lilly is a new event venue opening this fall in downtown Austin. (Courtesy Brian Cole Photography) Tiger Lilly, a new ...
Peninsula Daily News
6h
ATHLETES OF THE WEEK: Andrew Perez-Lopez, Quilcene football, and Lilly Anne Lancaster, Port Angeles girls soccer
This week, we recognize a pair of athletes who came through in the clutch for their teams in dramatic victories.
2d
on MSN
Jim Cramer Reports That Eli Lilly and Company (LLY)’s Donanemab Was Approved in Japan For Treating Early Symptomatic Alzheimer’s Disease
Stocks to Watch. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Japan
United States
Ebglyss
Alzheimer
Novo Nordisk
Feedback